Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 10/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 10/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7124863 | 0.93 | MAPT (0.46) | ADRB1ADRB3ADRB2MEN1GAA | |
| SCHEMBL7124858 | 0.92 | ADRB1 (0.47) | ADRB1ADRB3ADRB2MEN1GAA | |
| SCHEMBL7118226 | 0.92 | MAPT (0.50) | ADRB1ADRB3ADRB2MEN1GAA | |
| SCHEMBL7118263 | 0.87 | ADRB3 (0.54) | AGERADRB1ADRB3ADRB2MEN1 | |
| SCHEMBL7117697 | 0.82 | ADRB3 (0.54) | ADRB1ADRB3ADRB2MEN1GAA | |
| SCHEMBL7117695 | 0.81 | ADRB3 (0.53) | ADRB1ADRB3ADRB2MEN1GAA | |
| SCHEMBL7118196 | 0.80 | ADRB3 (0.56) | ADRB1ADRB3ADRB2MEN1MAPT | |
| SCHEMBL7018991 | 0.77 | MAPT (0.50) | ADRB1ADRB3ADRB2MAPTALDH1A1 | |
| SCHEMBL7018996 | 0.77 | MAPT (0.50) | ADRB1ADRB3ADRB2MAPTALDH1A1 | |
| SCHEMBL7122452 | 0.76 | ADRB1 (0.41) | ADRB1ADRB3ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6569873-B2 | Treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia, atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination | WYETH | 2003-05-27 | — | — | US | disclosed |
| US-6465501-B2 | USEFUL IN TREATING OR INHIBITING METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA, ATHEROSCLEROSIS, GASTROINTESTINAL DISORDERS, NEUROGENETIC INFLAMMATION, GLAUCOMA, OCULAR HYPERTENSION AND INCONTINENCE | WYETH | 2002-10-15 | — | — | US | disclosed |
| US-20020032222-A1 | Azolidines as beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-14 | — | — | US | disclosed |
| WO-2002006258-A1 | AZOLIDINES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032222-A1 | Azolidines as beta-3 adrenergic receptor agonists | GPR119, ADRB1, ADRB3 | AGER 180/4885ADRB1 2/4885ADRB3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.